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A B S T R A C TBackground: The Colombian health care system has had a plan with
limited beneﬁts, but since 2012, 57 drugs have been added to this plan.
Objectives: The objective of this article was to describe the trends of
utilization and costs of medications covered by the Agreement
029/2011 and compare them with those that were contained in the
beneﬁts plan. Methods: This descriptive study involved a group of
3.8 million people afﬁliated with the Colombian health care sys-
tem, in 110 cities from July 2011 until June 2013. The variables were
new medications that were included, comparing them with homo-
logous medications that were already in the plan, age, sex, dispensed
quantities, and monthly billing. The study established the deﬁned
daily dosage per thousand inhabitants per day, cost per thousand
inhabitants per day, cost per capita, and the rate of adoption or
replacement medicines. Results: The growth in the consumption of
new medications was 830.0%. The deﬁned daily dosage per thousand
inhabitants per day grew from 4.3 to 42.9, with an increase of 905.5%.ee front matter Copyright & 2015, International S
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ndence to: Jorge Enrique Machado-Alba, Calle 105,Medications with the highest growth were losartan/hydrochl-
orothiazide (15,723%), esomeprazole (4193%), atorvastatin (1402%),
and sertraline (298%). There was an increase of US $16.40 in the
cost per thousand inhabitants per day, which is equivalent to
an increase of 61.7% and represents a rise of US $0.49 in cost per
capita per month. Conclusions: The consumption behavior of new
medications and the economic implications for Colombia can be
demonstrated. In particular, the growth in the consumption of
medications for chronic diseases can be seen, which would represent
an increase of US $22.6 million per month to the entire population of
the country.
Keywords: Colombia, health services accessibility, economics,
pharmaceutical, pharmacoepidemiology.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Upon issuance of Law 100 of 1993, a basic package of services,
processes, health technologies, and drugs for all persons afﬁli-
ated with the Health System of Colombia (Sistema General de
Seguridad Social en Salud [SGSSS]) was created, known as the
Mandatory Health Plan (Plan Obligatorio de Salud [POS]) [1]. This
included the most essential drugs proposed by the World Health
Organization, under the approach of evidence-based medicine
[2,3]. The POS regulates the entirety of medications to which
individuals have access and has the limitations that are peculiar
to a restrictive form for an insured population. In certain cases in
which the prescribed medications were not on the list, there is a
possibility to use legal tools (Scientiﬁc-Technical Committees
[comités técnico cientíﬁcos (CTCs)] and Legal Failures or “tutela”)
to access them [4]. The SGSSS is based on the universal insuranceof around 47 million inhabitants through the provision of con-
tributions from the worker and the employer to a special fund
that holds the resources and the services are offered by Health
Promoting Entities (Entidades Promotoras de Salud [EPS] or
insurance companies) and health care facilities and hospitals
(IPS) and is divided into a contributory regime and one subsidized
by the state [1].
The Manual of Medicines of the POS had been undergoing
small changes over the years, until the Ministry of Health issued
the Agreement 029 of 2011, which substantially expanded the list.
In total, 196 new technologies were including procedures, med-
ical devices, and medicines, including 57 active novel principles
in 114 different pharmaceutical forms and also 14 different
pharmaceutical forms for drugs that were previously included
[5]. Previously, people had access to these drugs only by CTCs and
tutelas. The inclusion of medications of the Agreement 029/2011ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H R E G I O N A L I S S U E S 8 C ( 2 0 1 5 ) 2 8 – 3 5 29in the POS was done to reduce the economic impact of recoveries
to the Solidarity and Guarantee Fund (FOSYGA—entity in charge
of collecting resources from the SGSSS), shifting those costs to
the EPS through the capitation payment unit (UPC) made by
subscribers to the SGSSS.
This list, which was applied from January 2012, included
antibiotics, antihypertensives, lipid-lowering drugs, antidiabetic
medications, antirheumatics, anticancer vaccines, antimalarials,
antipsychotics, and anticonvulsants, among others. For some of
the medications, some restrictions were established, such as
their use in certain pathologies, conditions, or specialties, which
changed the prescribing patterns for general practitioners and
specialists [5].
Variations in the use of drugs may respond to different
conditions related to the most prevalent morbidities in a region,
and economics and cultural factors, as well as habits of prescrib-
ers; these had important consequences on health expenditure
factors. It should be noted that costs related to the payment for
drugs corresponded to one of the ﬁrst lines in the general
expenditure of resources of the SGSSS, and the inclusion of
new molecules should generate an additional load on the sector
[6,7].
Because of the recent measurement and the implications it
may have on the resources and ﬁnancing of the health sector, it
was our objective to describe the trends in the utilization and
costs of medications included in the Agreement 029/2011 and
compare them with those medications that were considered
homologous and were already in use at the POS, in a population
of people afﬁliated with the contributive regime of the SGSSS
during the ﬁrst 18 months of implementation [1,5,7].T
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A descriptive study was undertaken that followed an estimated
population that was the universe of people afﬁliated to the SGSSS
who were dispensed drugs and corresponded to 3.4 million
people in January 2011 and has been growing steadily; in January
2012, the population reached 3.7 million and in June 2013 it had
increased further to include 3.8 million people enrolled in six
different EPS. Overall, this corresponds to approximately 19.0% of
the population covered by the contributory regime of the SGSSS
and 8.2% of the Colombian population. The remaining 91.8% of
the population is afﬁliated to the SGSSS, and it receives medi-
cines from other providers of care. The dispensing data were
analyzed for the years 2011 to 2013 to include all users who
received any medication included in the Agreement 029/2011 in
110 cities (20 department capitals and 90 municipalities).
From the database of drugs that are delivered used by
Audifarma S.A., the largest dispenser of medicines in the country,
patients and formulations under investigation were reviewed,
including individuals of any age and sex who were receiving
drugs called counterparts or homologous to have the same
therapeutic indication from July 1, 2011, and new inclusions from
January 1, 2012, to June 30, 2013. Dispensing of drugs by CTCs and
tutelas was taken into account to determine the consumption
before it was included in the POS. This created a new database
that included the following variables:
New medications were dispensed according to the Anatomical
Therapeutic Chemical classiﬁcation. Considering these new drugs
included in the Agreement 029/2011 as drugs being monitored and
comparing their consumption with their corresponding counterpart
or homologue, they are deemed the same or different equivalent
medications as those in the Anatomical Therapeutic Chemical
group, but with a similar indication, and which were listed in
the previous POS. Therefore, the search included amoxicillin/
clavulanate versus amoxicillin; atorvastatin versus lovastatin;
Fig. 1 – Consumption trends per dosage per 1000 inhabitants per day, comparing the new medication included in the
Agreement 029/2012 versus a similar mandatory health plan (Colombia 2011–2013).
V A L U E I N H E A L T H R E G I O N A L I S S U E S 8 C ( 2 0 1 5 ) 2 8 – 3 530azithromycin versus erythromycin; carvedilol versus metoprolol;
cefuroxime versus cephalexin; clarithromycin versus erythromycin;
doxazosin versus prazosin; entacapone/levodopa/carbidopa versus
levodopa/carbidopa; esomeprazole versus omeprazole; lamotrigine
versus valproic acid; latanoprost versus timolol; losartan/hydro-
chlorothiazide versus losartan and hydrochlorothiazide in individ-
ual presentations; olanzapine versus clozapine; risperidone versus
clozapine; rivastigmine (no counterpart); sertraline versus ﬂuoxe-
tine; brimonidine versus timolol; valaciclovir versus acyclovir;
insulin aspartat, glulisine, or lispro versus insulin human zinc;
insulin glargine or insulin detemir versus zinc isophane or Neutral
Protamine Hagedorn (NPH); bosentan (no counterpart); etanercept
versus methotrexate; leﬂunomide versus methotrexate; mycophe-
nolate mofetil versus cyclosporine; and zoledronic acid versus
ibandronic acid. Also, new presentations that included medications
that were previously found in the beneﬁt plan were considered
(betametildigoxine, ibuprofen, omeprazole). The study excluded
medicines for hospital use and special programs in public health
because there was no representative on the outpatient dispensary.
Variables such as age, sex, number of patients, amounts
dispensed, and monthly billing costs for each drug were identi-
ﬁed. To evaluate the use of each drug, a daily deﬁned dose
established by the World Health Organization as an international
standard for the conduct of pharmacoepidemiological studies
was used; also, a number of daily deﬁned dose per thousand
inhabitants per day (DID) was used. For the overall assessment of
consumption in the POS, the manual algebraic sum of the DID of
all drugs tested and their counterparts was used.
The rate of adoption or replacement was estimated by taking
the percentage of users of the new technology in the last quarter
of observation (April–June 2013) minus the same percentage in
the last quarter of 2011, the period immediately preceding the
entry into force of Agreement 029/2011. It was assumed that all
the patients are users of the new technology plus the users of the
counterpart. The rate of adoption was not estimated in cases in
which it was not possible to establish a homologous content in
the previous beneﬁt plan or in which the consumption of the
deﬁned homologous medications was not found.
The estimation of the economic impact was expressed in
terms of cost per thousand inhabitants per day (CID)—CID ¼
(cost/30  No. of inhabitants)  1000—and per capita cost. The
resulting variation was the budgetary impact of the drug’s
inclusion [8]. For the conversion of monthly and annualinvestment in US dollars, the historical information of represen-
tative market rate (TRM) was used, as well as data from the last
business day of each month and year published by the Central
Bank (Banco de la República) on its Web site (TRM Last quarter
2013: colombia pesos (COP) $1862.51 per US $1).
The database was reviewed by the Department of Pharmacoe-
pidemiology of the company responsible for pharmaceutical
delivery (Audifarma S.A.). Changes in proportions and rates were
estimated using an Excel 2010 spreadsheet (Microsoft Windows).
The protocol was classiﬁed as safe research as regulated by
Resolution 8430/1993 of the Ministry of Health of Colombia,
following the principles established by the Declaration of Helsinki.Results
Before the application of Agreement 029/2011, a total of 13,836
people received some medications that were included, of which
6437 (46.5%) were female, 6895 (49.8%) were male, and 3.6% had
not registered their sex; also, 7003 (50.6%) belonged to group older
than 45 years. At the end of the observation period, the number
of patients who received the same medications, now included in
the POS, grew to 114,844, showing an increase of 830.0%. The
proportion of women who were receiving these drugs increased
to 58.5% (n ¼ 67,238), the proportion of men who were receiving
these drugs was reduced to 39.4% (n ¼ 45,220), and 2.1% of the
patients did not register their sex. In addition, the proportion of
users older than 45 years rose slightly to 52.9%. The demographic
characteristics of these populations are presented in Table 1.
In regard to the patients who used the counterparts, the
average number went down from 317,557 to 313,551, a decline
of 1.3%. The insured population, however, went from 3,627,853 to
3,816,475, an increase of 5.0%. In relative terms, users of counter-
parts, with respect to the insured population, accounted for 8.8%
in 2011 and were reduced to 8.2% in 2013. In 2011, it was found
that the average level of counterparts received by patients was
1.7%, showing a variation of 1.6%.
When evaluating the behavior of the sum of the DID of the new
medications included in the POS, it was observed that it rose from
4.3 DID at the end of 2011, when they were not yet included, to 42.9
DID for the ﬁrst half of 2013. This means that utilization grew
905.5%. It is important to note that at the same time although a
signiﬁcant growth in medications of the Agreement 029/2011
Table 2 – Variation in utilization and cost between new drugs of Agreement 029/2011 and their counterpart in the mandatory health plan (Plan
Obligatorio de Salud) (Colombia, 2011–2013).
New drugs
Agreement 029/
2011
DDD
variation
% DDD
variation
Cost
variation
(CID)
Cost
variation
(per capita)
% Cost
variation
Counterpart
drugs
DDD
variation
% DDD
variation
Cost
variation
Cost
variation
(per capita)
% Cost
variation
Rate of
adoption
(%)
Amoxicillin/clavulanic
acid
0.05 557 0.158 0.005 534 Amoxicillin 0.45 12 0.085 0.003 25 1.2
Atorvastatin 20.29 1402 1.068 0.032 361 Lovastatin 6.97 48 0.102 0.003 42 47.6
Azithromycin 0.06 2372 0.02 0.001 1831 Erythromicin 0.02 6 0.011 0 16 12.8
Metildigoxin 0.03 144 0.038 0.001 319 Metildigoxin 0.08 23 0.013 0 9 15.5
Carvedilol 0.98 391 0.085 0.003 51 Metoprolol 1.43 14 0.004 0 2 10.3
Cefuroxime 0.01 178 0.009 0 81 Cefalexin 0.02 1 0.035 0.001 9 0.1
Clarithromycin 0.15 80 0.108 0.003 216 Erythromicin 0.02 6 0.011 0 16 13.7
Doxazosin 0.03 204 0.006 0 76 Prazosin 0.02 3 0.003 0 8 1.8
Entacapone/levodopa/
carbidopa
0.06 115 0.43 0.013 130 Levodopa þ
carbidopa
0.04 10 0.013 0 15 13
Esomeprazole 8.26 4193 0.53 0.016 265 Omeprazole 8.38 29 0.096 0.003 22 29.4
Ibuprofen 0.63 144314 0.036 0.001 20743 Ibuprofen 0.18 12 0.004 0 7 23.8
Lamotrigine 0.04 22 0.118 0.004 34 Valproic acid 0.1 11 0.015 0 5 4.5
Latanoprost 0 0.152 0.005 101 Timolol 0 0.002 0 8 16.4
Losartan/
hydrochlorothiazide
2.57 15723 0.177 0.005 807 Losartan 0.65 1 0.019 0.001 3 4.5
Olanzapine 0.06 52 0.029 0.001 -16 Clozapine 0.05 9 0.005 0 3 2.3
Omeprazole 0.4 5383 0.308 0.009 3070 Omeprazole 8.38 29 0.096 0.003 22 0.7
Risperidone 0.08 88 0.46 0.014 67 Clozapine 0.05 9 0.005 0 3 7.3
Rivastigmine 0.34 590 1.3 0.039 452 0
Sertraline 1.83 815 0.083 0.002 189 Fluoxetine 1.03 20 0.004 0 4 24.9
Brimonidine 0 0.096 0.003 341 Timolol 0 0.002 0 8 4.1
Valaciclovir 0 46 0.005 0 25 Aciclovir 0.01 16 0.002 0 10 0.8
Insulin aspart 0.17 354 0.311 0.009 312 Insulin (human) 0.41 38 0.046 0.001 24 11.4
Insulin detemir 0.31 941 0.891 0.027 777 Insulin (human)
NPH
1.18 31 0.079 0.002 12 7.4
Insulin glargine 1.46 298 4.678 0.14 291 Insulin (human)
NPH
1.18 31 0.079 0.002 12 28.3
Insulin glulisine 0.41 277 0.715 0.021 270 Insulin (human) 0.41 38 0.046 0.001 24 21.6
Insulina lispro 0.17 141 0.257 0.008 145 Insulin (human) 0.41 38 0.046 0.001 24 7.7
Bosentan 0 50 1.109 0.033 57 0
Etanercept 0.07 115 3.166 0.095 107 Metotrexate 0.2 25 0.039 0.001 65 3.9
Leﬂunomide 0.13 60 0.037 0.001 6 Methotrexate 0.2 25 0.039 0.001 65 6.7
Mycophenolate 0.02 11 0.185 0.006 4 Ciclosporin 0 1 0.147 0.004 18 3.4
Midazolam 0 45 0.002 0 58 Diazepam 0.00005 5 0 0 5 5.3
Omeprazole for
injection
0.01 298 0.007 0 139 Ranitidine 0.001 6 0.001 0 8 4.5
Glucagon 0 26 0.001 0 19 0
Metoprolol for
injection
0 151 0 0 90 0
Norepinephrine 0 19 0 0 5 Epinephrine 0.02 44 0.002 0 46 0.2
Iopromide 0 0 0 0
Cefuroxime for
injection
0 607 0.001 0 476 Cefalotin 0.001 38 0.006 0 45 1.1
Gadolinium 0 0.004 0 569 0
Caspofungin 0 206 0.021 0.001 206 Amphotericin b 0 0 0
Esomeprazole for
injection
0 217 0.001 0 146 Ranitidine 0.001 6 0.001 0 8 0.1
Cefepime 0 320 0.019 0.001 265 Ceftriaxone 0.01 27 0.002 0 4 1.5
continued on next page
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V A L U E I N H E A L T H R E G I O N A L I S S U E S 8 C ( 2 0 1 5 ) 2 8 – 3 532occurred, a reduction in the counterparts that were previously
included in the manual of drugs was also seen, from 133.2 DID to
114.5 DID, which corresponds to a decrease of 18.7% (Fig. 1).
Table 2 presents the list of new drugs included in Agreement
029/2011, with variation in the DID. The list includes the follow-
ing: the percentage that represents that variation on the DID, the
variation of the per capita cost of each of them, variations in the
CID, and the percentage of this variation. It can be observed that
some of those medications showed an increase as well as a
decrease. In the ﬁrst part of the table, the counterparts for each
new medication product can be clearly seen, with the same
indicators showing the consumption variation, the costs, the
overall variation of CID, and the per capita cost.
The medications that showed a greater growth corresponded
to atorvastatin (increase 20.3% DID equivalent to a growth rate of
1402%), esomeprazole (increase 8.3% DID, 4193%), losartan þ
hydrochlorothiazide (increase 2.6% DID, 15,723%), sertraline
(increase 1.8% DID, 815%), and insulin glargine (increase 1.5%
DID, 298%). The main reduction was observed in medicines such
as omeprazole (8.4% DID, reduction of 29%), lovastatin (7.0%
DID, reduction of 48%), ﬂuoxetine (1.0% DID, reduction of 20%),
and NPH insulin (1.2% DID, reduction of 31%) (Fig. 2A–D).
The medications that showed the highest rates of adoption
were atorvastatine (47.6%), capecitabine (34.2%), esomeprazole
(29.4%), glargine insulin (28.3%), and sertraline (24.9%). The
average rate of adoption was 10.2%, and the upper 25 percentile
was 26.0% (Table 2).
The impact on costs was estimated by comparing differences
in consumption among the second trimester of 2013 and the last
trimester of 2011. Here, a growth of US $16.40 per 1000 inhabitants
and day (new medications US $16.82 CID; counterparts –US $0.42
CID) was observed. This is equivalent to an increase of 61.7% in the
costs and represents an increase of US $0.49 monthly in the cost
per capita (CPC) (US $0.50 new and US $0.01 counterparts) (Fig. 3).
The medications that had the highest costs were glargine (US
$4.68 CHD; US $0.14 CPC), etanercept (US $3.17 CHD; US $0.09
CPC), rivastigmine (US $1.30 CHD; US $0.04), bosentan (US $1.11
CHD; US $0.03 CPC), and atorvastatine (US $1.07 CHD; US $0.03
CPC). It was therefore necessary to estimate the total variation in
the costs to adjust the average to the behavior of the counterparts
(Table 2).Discussion
This is the ﬁrst study to show the consumption behavior of new
medications included in the POS and the economic implications
that it has had in Colombia. The growth in pharmaceutical
expenditure for the health care system is a global trend [9]. On
the one hand, access to medicines is crucial to ensure the
constitutional rights of health, but on the other hand, the
increase in expenses can lead to a health system collapse and
insufﬁcient resources to achieve the objectives of the health
system. The results of this analysis showed a signiﬁcant increase
in the use of newly incorporated drugs, which is 10 times greater
in 18 months, thus undoubtedly inﬂuencing the per capita cost
and therefore the UPC [6].
For each additional daily deﬁned dose per 1000 inhabitants
per day of growth in the use of drugs of Agreement 029/2011, an
increase of US $0.43 per 1000 inhabitants per day in the cost (US
$0.01 per capita/mo) is generated. This should be compared with
the previously observed results for homologous medications: for
each DID that increased the medications, a reduction of 0.48 in
the use of the homologues was presented. On the issue of costs,
for each DID reducing the use of past medications, however, only
a decrease of US $0.02 (US $0.001 per capita/mo) was observed;
therefore, there is no economic compensation by performing
Fig. 2 – Consumption trend per dosage per 1000 inhabitants per day, comparing atorvastatin versus lovastatin (A),
esomeprazole versus omeprazole (B), sertraline versus ﬂuoxetine (C), and insulin glargine versus insulin isophane zinc (NPH).
DHD, Dose inhabitant per day; NPH, Neutral Protamine Hagedorn. (Colombia 2011–2013).
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Fig. 3 – Cost trends per 1000 people per day compared with new medications including the Agreement 029/2012 versus the
mandatory health plan, Colombia (2011–2013).
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case of the Colombian system, the increase in spending on drugs
by 61.7% exceeds the data reported by countries such as the
United Kingdom (up by 10% in 2002) [10] and Canada (6.0% in
2006) [11,12], but is less than that reported by Brazil between 2002
and 2006, where drug spending grew by 123.9% [9].
Some countries have reported a signiﬁcant increase in spend-
ing on medicines for HIV infection/AIDS, rheumatoid arthritis,
multiple sclerosis, diabetes mellitus, mental disorders, neurolog-
ical diseases, and hemophilia [6,9,13,14]. In this study, the increase
in spending on medicines was due to medications for multiple
conditions: bacterial, viral, and fungal infections; Parkinson’s
disease; seizure disorders; schizophrenia; Alzheimer’s disease;
depressive disorders; glaucoma; arterial hypertension; acid peptic
disease; diabetes mellitus; transplant rejection; rheumatoid arthri-
tis; pulmonary hypertension; and cancer, which is consistent with
what others authors have reported [6,9,14]. Although technological
progress can reduce costs in the beginning, it is true that it tends
to introduce more expensive treatments and comprehensively
promote employment, resulting in an increase in spending on
health, particularly with regard to drugs [15].
Some of the drugs included in the listing are new innovations
for users who did not previously have alternative therapies, such
as for Alzheimer’s disease, for pulmonary hypertension, or for
those who were being treated with drugs that were superseded
by new options for glaucoma, cancer, transplant rejection, epi-
lepsy, and psychosis [5]. It is not within the scope of this research
to describe the causes of the observed increases. Factors such as
accessibility to prescription without the need to provide medical
justiﬁcations (the CTC), the lack of management guidelines to
perform therapeutic advances, and real innovations for POS,
among others, however, may have had an impact on the
increased prescription of new drugs [15–17].
The recent economic crisis has severely affected many coun-
tries and has affected the health systems in particular. Because of
this new context, governments have been forced to rethink how
they are going to invest and spend their resources. In Europe, for
example, the governments are forcing pharmaceutical companies
to reduce the costs of medication and have established systems
with more efﬁcient price control, have limited medications that
they are willing to ﬁnance, and have established systems of co-
payments for users [12,18–20]. Also, strategies have been imple-
mented to modify the behavior of the prescribers, improve the
quality of care, control expenses through the inclusion and
dissemination of clinical practice guidelines, and perform audit
with feedback and educational visits to doctors [15–17].Another mechanism used in several countries of the world is
health technology assessments for the inclusion of technologies
in the beneﬁts plan of the health systems. These evaluations are
based on cost-effectiveness methods and also communicate the
budget impact that technologies generate in the health system.
This methodology was used partially for the Commission Health
Care Regulating in Colombia (CRES). Several comments have been
previously made about this process [21].
The increase in the use of new technologies in health in the
POS has a direct economic impact, which, in addition to display-
ing an accelerated growth, has an impact on the resources of the
SGSSS, now from the capitation payment unit (UPC) correspond-
ing to the value that each insured person pays to the health
system per year. This information should be of vital importance
to decision makers faced with the need of maintaining these
drugs that have been included and possible new drugs to include
in the beneﬁts plan. In many health care systems, such as in the
United Kingdom, Australia, France, Belgium, and Taiwan, there is
a mechanism for reimbursement by the health authorities. This
mechanism contemplates the option of reversibility of the deci-
sions in accordance with the achievement of results expected;
this approach of coverage with evidence has not been considered
in the Colombian SGSSS [19,22].
To reduce the ﬁnancial burden faced by the insurers and
payers or to facilitate the rational use of medicine, the resources
may be reassigned to health care services as a priority, according
to the morbidity proﬁle; this can improve health and conserve
resources. The results of policies for controlling the expenditure
on medications, however, are multidimensional and their suc-
cess should be measured by not only their impact on the
consumption and cost of the drugs but also their effects on the
health of the people, the use of health services, and costs for
patients [12].
It can be concluded that there has been an increase in the use of
new drugs included in the POS through the Agreement 029/2011,
especially because of the use of drugs for chronic diseases, includ-
ing atorvastatin, esomeprazole, the combination of losartan and
hydrochlorothiazide, sertraline, and insulin glargine, among others.
This increase has generated a remarkable economic impact, calcu-
lated to be US $16.40 per 1000 inhabitants per day (US $0.49 per
capita per month), which is above the growth observed in the
consumption of the counterparts. This type of study serves as a tool
for the evaluation of health policies at the national level in the ﬁeld
of medicinal products. But people who make decisions on the
health system about the inclusion of new drugs should consider
these results to perform economic analyses and explore the need
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ﬁnanced by the SGSSS. It is important to point out that even though
the population studied is not statistically representative of the total
of the Colombian population, extrapolation of the results only to
the contributory scheme would result in an increase of US $9.74
million per month and a monthly increase of US $22.63 million.
It is necessary to consider that one of the limitations of the
study is statistically representative data not being available for
the general population in Colombia; however, because this was
not part of the objectives of this work, it can be added that the
information refers to the situation of drug consumption, with
19% of the population afﬁliated to the contributory scheme, but
only 8% of total Colombians; this is a limitation for the inter-
pretation of the data in populations that belong to the subsidized
regime or are afﬁliated with other EPS.
Source of ﬁnancial support: Audifarma S.A. supported
this study.
R E F E R E N C E S[1] Ministerio de Salud de Colombia. Consejo Nacional de Seguridad Social
en Salud. Acuerdo 228 de 2002. Available from: http://www.col.ops-oms.
org/medicamentos/Documentos/ac228_02.htm. [Accessed November 1,
2011].
[2] Laing R, Waning B, Gray A, et al. 25 years of theWHO essential medicines
lists: progress and challenges. Lancet 2003;361:1723–9.
[3] Seuba X. A human rights approach to the WHO Model List of Essential
Medicines. Bull World Health Organ 2006;84:405–7.
[4] Hogerzeil HV, SamsonM, Vidal Casanovas J, Rahmani-Ocora L. Is access to
essential medicines as part of the fulﬁllment of the right to health
enforceable through the courts? Lancet 2006;368:305–11.
[5] Comisión de Regulación en Salud. República de Colombia. Acuerdo 029
de 2011. Available from: http://www.minsalud.gov.co/salud/POS/
Documents/sitio/ACTUALIZACI%C3%93N%20POS%202012/Acuerdo%
20029%20de%202011.pdf. [Accessed March 3, 2013].
[6] Machado Alba JE, Moncada Escobar JC. [Evolution of consumption of high-
cost drugs in Colombia] [Article in Spanish]. Rev Panam Salud Pública
2012;31:283–9.
[7] Ministerio de Salud de Colombia. Consejo Nacional de Seguridad Social en
Salud. Acuerdo 0336 de 2006. Available from: http://www.icbf.gov.co/cargues/avance/docs/acuerdo_cnsss_0336_2006.htm. [Accessed November
1, 2011].
[8] Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice
for budget impact analysis: report of the ISPOR Task Force on good
research practices–budget impact analysis. Value Health
2007;10:336–47.
[9] Vieira FS. Ministry of Health’s spending on drugs: program trends from
2002 to 2007. Rev Saude Publica 2009;43:674–81.
[10] Macdonald S. Increased drug spending is creating funding crisis, report
says. BMJ 2003;326:677.
[11] Kondro W. Drug spending tops $25 billion. CMAJ 2007;176:1816.
[12] Austvoll-Dahlgren A, Aaserud M, Vist G, et al. Pharmaceutical policies:
effects of cap and co-payment on rational drug use. Cochrane Database
Syst Rev 2008(1):CD007017.
[13] Lu CY, Williams KM, Day RO. Access to tumour necrosis factor
inhibitors for rheumatoid arthritis treatment under the Australian
Pharmaceutical Beneﬁts Scheme: are we on target? Intern Med J
2006;36:19–27.
[14] Gleason PP, Alexander GC, Starner CI, et al. Health plan utilization and
costs of specialty drugs within 4 chronic conditions. J Manag Care Pharm
2013;19:542–8.
[15] de Meijer C, O’Donnell O, Koopmanschap M, van Doorslaer E. Health
expenditure growth: looking beyond the average through decomposition
of the full distribution. J Health Econ 2013;32:88–105.
[16] Lewin S, Lavis JN, Oxman AD, et al. Supporting the delivery of cost-
effective interventions in primary health-care systems in low-income
and middle-income countries: an overview of systematic reviews.
Lancet 2008;372:928–39.
[17] Cecil WT, Barnes J, Shea T, Coulter SL. Relationship of the use and costs
of physician ofﬁce visits and prescription drugs to travel distance and
increases in member cost share. J Manag Care Pharm 2006;12:665–76.
[18] Sharma D, Martini LG. Austerity vs. growth–the impact of the current
ﬁnancial crisis on pharmaceutical innovation. Int J Pharm
2013;443:242–4.
[19] Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence
development, only in research, risk sharing, or patient access scheme?
A framework for coverage decisions. Value Health 2012;15:570–9.
[20] Molina-Mula J, De Pedro-Gómez JE. Impact of the politics of
austerity in the quality of healthcare: ethical advice. Nurs Philos
2013;14:53–60.
[21] Fundación instituto para la investigación del medicamento en los sistemas
de salud – Ifarma. Anexo Técnico. Inclusiones de medicamentos
incorporados en el Plan Obligatorio De Salud (POS) – Acuerdo 029 De
2011. 2012. Available from: http://www.viva.org.co/pdfs/comision_
salud/documento_ifarma.pdf. [Accessed November 1, 2011].
[22] Sun Q, Santoro MA, Meng Q, et al. Pharmaceutical policy in China.
Health Aff (Millwood) 2008;27:1042–50.
